Next Generation Personalized Neuroblastoma Therapy

Inclusion Criteria

• •Aged ≥1 years to ≤ 21 years
• •Relapsed or refractory neuroblastoma
• •A sufficient interval between the last dose of prior anti-cancer therapy (including cytotoxic and biological therapies) and enrollment in this study, to allow recovery from the acute toxic effects of all prior anti-cancer therapy. Please contact site for specific details
• •Adequate bone marrow function (bone marrow may be involved with tumor. Contact site for specific details)
• •Adequate renal function, defined as Creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥ 70 mL/min/1.73 m2 OR serum creatinine based on age/gender normal (contact site for details)
• •Adequate liver function, defined as total serum bilirubin ≤ 1.5 times the upper limit of normal AND alanine transaminase (ALT) ≤ 110 U/L.
• •Adequate cardiac function, defined as corrected QT interval (QTc) ≤ 480 msec AND shortening fraction \> 27%
• •Males and females who are sexually active must agree to use effective contraception during and for 3 months after treatment